ClinicalTrials.gg
Not yet recruitingNCT04007276Updated Oct 13, 2026

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

A Phase 4 interventional study of brimonidine tartrate ophthalmic solution 0.025% and sterile balanced saline solution in Glaucoma, Glaucoma, Open-Angle and Glaucoma; Drugs, sponsored by Tulane University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionGlaucoma, Open-AngleRegistry: GlaucomaReclassifiedWhy we changed it
Registry
Glaucoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Glaucoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tulane University · Phase 4, Interventional, and Treatment

How we know

Updated Oct 13, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing brimonidine in Glaucoma, Open-Angle — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma, Open-Angle.

Planned enrollment
13th of 17
60 · median 120
Started
2027
the only one that year
Phase 4
11 of 18
1 open now
Registered
17th of 18
by date

Among the 18 studies testing brimonidine in Glaucoma, Open-Angle, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 11 in phase 4, and was the 17th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 18 studies testing brimonidine in Glaucoma, Open-Angle is open now, in 1 country.

By country, each count listing its studies:

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing brimonidine in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.

03

Conditions studied

  • Glaucoma
  • Glaucoma, Open-Angle
  • Glaucoma; Drugs
  • Droopy Eyelid
  • Ptosis
  • Glaucoma, Primary Open Angle

Browse trials for

04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's planned enrollment of 60 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Tulane University is the lead sponsor of 96 studies on the registry; 23 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glaucoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • Diagnosis of primary open angle glaucoma
  • Willing and able to give
  • Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Prisoners
  • Known allergy or sensitivities to brimonidine
  • No surgery within the past 6 months
  • No history of lid surgery or botox
  • Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator
  • Inability to sit comfortably for 30 minutes
  • Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Lumify Arm

    In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.

    Drug: brimonidine tartrate ophthalmic solution 0.025%

  • Sham comparator
    Control Arm

    In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.

    Other: sterile balanced saline solution

Interventions

  • DrugBrimonidineStudies of BrimonidineBrimonidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.

    Also known as: Lumify™

  • Othersterile balanced saline solution

    Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.

07

What researchers measure

Primary outcomes

  1. Ocular redness

    Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)

    Time frame: 5 minutes after application of eye drop

  2. Ocular redness

    Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)

    Time frame: 15 minutes after application of eye drop

  3. Ocular redness

    Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)

    Time frame: 30 minutes after application of eye drop

  4. Ocular redness

    Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)

    Time frame: 60 minutes after application of eye drop

  5. Intraocular pressure

    Measurement of intraocular pressure using handheld tonometer (TonoPen)

    Time frame: 60 minutes after application of eye drop

Secondary outcomes

  1. Palpebral fissure height

    Measurement of distance between inner margin of upper and lower eyelids from clinical photographs

    Time frame: 60 minutes after application of eye drop

  2. Eye discomfort

    Subjective scoring of ocular discomfort by patient on a 0-10 unit scale (0 = very comfortable, 10 = very uncomfortable)

    Time frame: 60 minutes after application of eye drop

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2027; primary completion for Nov 2031, 48 months later.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 48 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Nov 2026 → Nov 2027, primary completion Jun 2031 → Nov 2031 and completion Jun 2036 → Nov 2036.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2019
First posted
Jul 5, 2019
StartEst.
Nov 2027was Nov 2026
Primary completionEst.
Nov 2031was Jun 2031
CompletionEst.
Nov 2036was Jun 2036
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 10, 2026→Nov 2027
Oct 13, 2026
Primary completion
Jun 1, 2031→Nov 2031
Oct 13, 2026
Study completion
Jun 1, 2036→Nov 2036
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Nov 10, 2026→Nov 2027
    Primary completion Jun 1, 2031→Nov 2031
    Study completion Jun 1, 2036→Nov 2036
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04007276
Lead sponsor
Tulane University
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Nov 2027 (estimated)
Primary completion
Nov 2031 (estimated)
Completion
Nov 2036 (estimated)
Last update
Oct 13, 2026

Study contacts

Ze Zhang, MD
Contact
zzhang9@tulane.edu
504-988-5831
Whitley Richardson
Contact
wrichardson@tulane.edu
504-988-2261
Ze Zhang, MD
principal investigator · Tulane University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion